Lupus & antiphospholipid syndrome

Risk of Bloodstream Infection in Patients with Systemic Lupus Erythematosus Exposed to Prolonged Medium-to-High-Dose Glucocorticoids

LupusPublished Retrospective cohort study

Authors' conclusion

In patients with SLE exposed to prolonged medium-to-high-dose glucocorticoids, the 1-year incidence rate of BSI was significantly higher than previously reported in the general patients with SLE. Severe disease activity, and high-dose glucocorticoid treatment previously or at baseline increased the risk of BSI.

Study context

Population
Patients with systemic lupus erythematosus (SLE) treated with prolonged (≥4 weeks) medium-to-high-dose GC (≥15 mg/day prednisolone), over 14 years
Participants
612 patients1,109 treatment episodes
Outcome
1-year incidence of BSI
Follow-up
1 year
Methodological detailsgeneralized estimating equation, multivariable analysis
  • Generalized estimating equation
  • Multivariable analysis

Main finding

As reported in the abstract

Incidence rate of BSI

Bloodstream infection (BSI) cases during 1078.64 person-years

30

Incidence rate of BSI per 100 person-years

2.78

95% CI 1.88–3.97

Observational data: associations, not effects.

Further findings

OutcomeValuesIRR (95% CI)
Mortality, treatment episodes with BSIvs other episodesEpisodes with BSI 16.7%19.59 (7.33–52.44)

Risk factors for BSI (multivariable analysis)

aIRR (95% CI)
SLEDAI-2K ≥204.66 (2.17–10.00)
Initial baseline prednisolone ≥ 60 mg/day2.42 (1.11–5.32)
Cumulative prednisolone dose ≥15 mg/day during previous 6 months2.13 (1.03–4.40)
Higher incidence rate of BSI as disease activity or baseline GC dose increased

Original publication

Risk of Bloodstream Infection in Patients with Systemic Lupus Erythematosus Exposed to Prolonged Medium-to-High-Dose Glucocorticoids. Lupus. Published 1 March 2023. doi:10.1177/09612033231160731

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.